E-LIB Suche - Ergebnisse für: Borja-Tabora, Charissa Fay

1

Safety, immunogenicity, and lot-to-lot consistency of a qua..:

Cadorna-Carlos, Josefina B. ; Nolan, Terry ; Borja-Tabora, Charissa Fay...
Vaccine. 33 (2015) 21 - p. 2485-2492 , 2015

Link: https://doi.org/10.1016/..

2

Influenza vaccine concurrently administered with a combinat..:

Lum, Lucy Chai See ; Borja-Tabora, Charissa Fay ; Breiman, Robert F....
Vaccine. 28 (2010) 6 - p. 1566-1574 , 2010

Link: https://doi.org/10.1016/..

3

A phase 2b/3b MenACWY-TT study of long-term antibody persis..:

Borja-Tabora, Charissa Fay Corazon ; Peyrani, Paula ; Webber, Chris...
BMC Infectious Diseases. 20 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

4

Efficacy, immunogenicity, and safety of a quadrivalent inac..:

Pepin, Stephanie ; Dupuy, Martin ; Borja-Tabora, Charissa Fay Corazon...
Vaccine. 37 (2019) 13 - p. 1876-1884 , 2019

Link: https://doi.org/10.1016/..

5

Long-term immunogenicity and safety after a single dose of ..:

Borja-Tabora, Charissa Fay Corazon ; Montalban, Cecilia ; Memish, Ziad A....
BMC Infectious Diseases. 15 (2015) 1 - p. , 2015

Link: https://doi.org/10.1186/..

6

A phase 2b/3b MenACWY-TT study of long-term antibody persis..:

Borja-Tabora, Charissa Fay Corazon ; Peyrani, Paula ; Webber, Chris...
https://repository.publisso.de/resource/frl:6439405. , 2020

Link: https://repository.publi..

7

A phase 2b/3b MenACWY-TT study of long-term antibody persis..:

Borja-Tabora, Charissa Fay Corazon ; Peyrani, Paula ; Webber, Chris...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301505/. , 2020

Link: http://www.ncbi.nlm.nih...

8

Long-term immunogenicity and safety after a single dose of ..:

Borja-Tabora, Charissa Fay Corazon ; Montalban, Cecilia ; Memish, Ziad...
http://www.biomedcentral.com/1471-2334/15/409. , 2015

Link: http://www.biomedcentral..

9

A phase 2b/3b MenACWY-TT study of long-term antibody persis..:

Charissa Fay Corazon Borja-Tabora ; Paula Peyrani ; Chris Webber...
http://link.springer.com/article/10.1186/s12879-020-05104-5. , 2020

Link: https://doi.org/10.1186/..

10

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-00..:

Sirivichayakul, Chukiat ; Biswal, Shibadas ; Saez-Llorens, Xavier...
The Journal of Infectious Diseases. , 2024

Link: https://doi.org/10.1093/..

11

Long-term efficacy and safety of a tetravalent dengue vacci..:

Tricou, Vianney ; Yu, Delia ; Reynales, Humberto...
The Lancet Global Health. 12 (2024) 2 - p. e257-e270 , 2024

Link: https://doi.org/10.1016/..

12

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequent..:

Sáez-Llorens, Xavier ; Biswal, Shibadas ; Borja-Tabora, Charissa...
The American Journal of Tropical Medicine and Hygiene. 108 (2023) 4 - p. 722-726 , 2023

Link: https://doi.org/10.4269/..

13

Safety and immunogenicity of SCB-2019, an adjuvanted, recom..:

Lopez, Pio ; Bravo, Lulu ; Buntinx, Erik...
Human Vaccines & Immunotherapeutics. 19 (2023) 1 - p. , 2023

Link: https://doi.org/10.1080/..

14

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-prote..:

Buntinx, Erik ; Brochado, Leonardo ; Borja-Tabora, Charissa...
Vaccine. 41 (2023) 11 - p. 1875-1884 , 2023

Link: https://doi.org/10.1016/..

15

A Phase 3, Multicenter, Randomized, Controlled Trial to Eva..:

Carlos, Josefina Cadorna ; Tadesse, Birkneh Tilahun ; Borja-Tabora, Charissa...
The Lancet Regional Health - Western Pacific. 24 (2022) - p. 100484 , 2022

Link: https://doi.org/10.1016/..